Glycoconj J
Glycoconjugate Journal
0282-0080
1573-4986
Springer US
Boston


2234449
17909966
9070
10.1007/s10719-007-9070-z
Article


Characterization of anticoagulant heparinoids by immunoprofiling

Wijnhoven
Tessa J.

1
2

van de Westerlo
Els M.

1

Smits
Nicole C.

1

Lensen
Joost F.

1

Rops
Angelique L.

3

van der Vlag
Johan

3

Berden
Jo H.

3

van den Heuvel
Lambert P.

2

van Kuppevelt
Toin H.

+31-24-3616759
+31-24-3540339
A.vankuppevelt@ncmls.ru.nl

1

1
Department of Matrix Biochemistry, Nijmegen Centre for Molecular Life Sciences, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands 
2
Department of Pediatric Nephrology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands 
3
Nephrology Research Laboratory, Division of Nephrology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands 

2
10
2007

2
2008

25
2
177
185
22
5
2007

20
8
2007

28
8
2007


© Springer Science+Business Media, LLC 2007

O
-sulfates) and HS4E4 (indicative for domains allowing anti-factor IIa activity). In addition, the immunoprofile could be indicative for heparinoid-induced side-effects, such as heparin-induced thrombocytopenia, as illustrated by reactivity with antibody NS4F5, which defines a very high sulfated domain. In conclusion, immunoprofiling provides a novel, fast, and simple methodology for the characterization of heparinoids, and allows high-throughput screening of (new) heparinoids for defined structural and biological characteristics.

Keywords
Antibody
Anticoagulation
Heparin-induced thrombocytopenia
Heparinoid
Immunoprofiling

issue-copyright-statement
© Springer Science+Business Media, LLC 2008




Introduction
N
d
N
N
N
l
O
27
32
].
S
S
S
S
S
S
5
23
37
23
2
5
10
22
2
5
10
22
24
28
4
24
6
7
23
].
1
12
17
Table 1
Characteristics of therapeutic heparinoids

Heparinoid: generic name (brand name)
Composition (and method of heparin modification)
Molecular weight, kDa


Heparin
Heparin
5.0–30.0

Dalteparin (Fragmin)
LMWH (deaminative cleavage with nitrous acid)
4.0–6.0

Nadroparin (Fraxiparine)
LMWH (deaminative cleavage with nitrous acid)
2.4–7.2

Enoxaparin (Clexane, Lovenox)
LMWH (β-eliminative cleavage by alkaline treatment)
3.5–5.5

Tinzaparin (Innohep, Logiparin)
LMWH (β-eliminative cleavage by heparinase)
3.4–5.6

Sulodexide (Vessel Due F)
a
, 20% DS
<8.0

Danaparoid (Orgaran)
84% HS, 12% DS, 4% CS
4.0–10.0

Fondaparinux (Arixtra)
31
43
3
10
8

1,728



All drugs are derived from porcine intestinal mucosa, with the exception of the chemically synthesized pentasaccharide fondaparinux.
LMWH
HS
DS
CS
 chondroitin sulfate
a
42
].



17
]. In general, these techniques require sophisticated instrumentation and sometimes extensive sample preparation. Alternative methodologies that are fast and simple are needed. Immunoprofiling of heparinoids could be a fast and simple method to characterize the complex heparinoids. Recently, a number of phage–display-derived antibodies were generated, reactive with various domain structures within heparin. In this study nine antibodies–all defining different heparin epitopes–were applied to study their reactivity with heparinoids.

Materials and methods
Heparinoids
1
.

Quantification of glycosaminoglycans by Farndale assay
13
]. To 50 μl of the standard (heparin, 0–100 μg/ml) and heparinoids 1 ml Farndale reagent (40.5 mmol/l glycine, 40.6 mmol/l NaCl, and 0.05 mmol/l 1,9-dimethylmethylene blue, pH 3.0) was added and absorbance was measured directly at 525 nm.

Determination of glycosaminoglycan classes by agarose gel electrophoresis
w
v
2
2
w
v
38
].

Enzymatic digestion of heparinoids
2
2
Flavobacterium heparinum
Proteus vulgaris
11
11
]. The solutions were incubated for 16 h at 37°C.

Determination of glycosaminoglycan size by polyacrylamide gel electrophoresis
36
w
v
v
v
38
].

Production of anti-heparin antibodies
2
41
8
43
39
et al.
15
8
41
Table 2
Characteristics of epitope-specific anti-heparin antibodies

Antibody
H
 CDR3 sequence
H
 family
DP gene
GAG used for selection
Essential modifications
Inhibitory modifications


HS4C3
GRRLKD
3
38
41
]
N
-sulfation
 

O
-sulfation (minor importance)

O
-sulfation

O
-sulfation

HS3A8
GMRPRL
3
38
8
]
N
-sulfation
 

C5-epimerization

O
-sulfation

O
-sulfation (likely)

HS4E4
HAPLRNTRTNT
3
38
8
]
N
-acetylation
O
a
O
-sulfation

N
-sulfation

C5-epimerization

LKIV69
GSRSSR
3
38
43
]
N
-sulfation
O
-sulfation

C5-epimerization (likely)

O
-sulfation

EW3D10
GRTVGRN
3
38
39
]
b



EW4G2
GKVKLPN
3
38
39
]
b



NS4F5
SGRKGRMR
3
53
c

N
-sulfation
 

C5-epimerization

O
-sulfation (high)

O
-sulfation (high)

AO4B08
SLRMNGWRAHQ
3
47
15
]
N
-sulfation
 

C5-epimerization

O
d


O
-sulfation (high)

RB4EA12
RRYALDY
3
32
15
]
N
-acetylation
 

N
-sulfation

O
-sulfation

MPB49 (control)
WRNDRQ
3
38
–
–




H
H
et al.
 unpublished results.
GAG
HS
 heparan sulfate
a
O
16
].
b
8
39
].
c
et al.
, unpublished results
d
O
16
].




Enzyme-linked immunosorbent assay
41
w
v
v
v
w
v
v
v
p
2
43
]. Background reactivity, measured with the control antibody MPB49, was substracted. The absorbance with control antibody MPB49 was comparable to the absorbance measured when primary antibody was omitted.

Immunofluorescence staining
43
].


Results
General biochemical analysis of heparinoids
1
1
42
Fig. 1
Agarose gel electrophoresis of heparinoids. The different classes of GAGs in the drugs were visualized by a combined azure A–silver staining procedure. The standard contains 40 ng HS, 20 ng DS, and 20 ng CS




2
O
2
Fig. 2
a
b
) heparinoids. Heparinoids were visualized by a combined alcian blue-silver staining procedure. Treatment with heparinase I resulted in cleavage of dalteparin and enoxaparin, whereas treatment with chondroitinase ABC did not. Sulodexide was cleaved by heparinase I as well as chondroitinase ABC





Characterization of heparinoids using anti-heparin antibodies
3
17
N
N
Table 3
Reactivity of anti-heparin antibodies with heparinoids (ELISA)

 
HS4C3
HS3A8
HS4E4
LKIV69
EW3D10
EW4G2
NS4F5
AO4B08
RB4EA12


Heparin
100
100
100
100
100
100
100
100
100

Dalteparin
75 ± 6
44 ± 4
8 ± 5
3 ± 1
33 ± 6
49 ± 8
0 ± 0
16 ± 4
13 ± 2

Nadroparin
29 ± 3
5 ± 2
4 ± 3
0 ± 0
3 ± 1
7 ± 4
0 ± 0
1 ± 1
1 ± 1

Enoxaparin
80 ± 9
56 ± 8
7 ± 3
10 ± 2
36 ± 8
26 ± 7
1 ± 1
28 ± 7
21 ± 6

Tinzaparin
84 ± 1
55 ± 2
8 ± 3
44 ± 10
45 ± 12
74 ± 1
9 ± 2
20 ± 3
25 ± 8

Sulodexide
102 ± 5
71 ± 11
283 ± 21
51 ± 7
43 ± 10
100 ± 3
0 ± 0
102 ± 15
26 ± 8

Danaparoid
69 ± 11
22 ± 3
58 ± 17
2 ± 2
2 ± 1
1 ± 1
0 ± 0
63 ± 6
3 ± 1



n
 = 4). Each hepainoid shows a distinct immunoprofile.



Heparinoids could be ranked according to their reactivity with antibodies. For instance, reactivity of antibody EW4G2 was highest with heparin and sulodexide, followed by tinzaparin, dalteparin, and enoxaparin. Reactivity with the other heparinoids was very low or absent. Antibody LKIV69 reacted strongly with heparin, followed by sulodexide and tinzaparin, whereas other heparinoids reacted poorly. Reactivity of antibody AO4B08 was highest with heparin and sulodexide, followed by danaparoid and enoxaparin/tinzaparin/dalteparin, whereas reactivity with nadroparin was absent. These data indicate that distinct heparin domain structures are present in different commercially available heparinoids.
S
S
S
S
S
S
S
4
N
N
O
O
N
O
O
O
i.e.
N
O
O
N
O
Table 4
Reactivity of anti-heparin antibodies with heparin and fondaparinux (competition ELISA)

 
HS4C3
HS3A8
HS4E4
LKIV69
EW3D10
EW4G2
NS4F5
AO4B08
RB4EA12


Heparin
0.3 ± 0.1
0.4 ± 0.1
2.7 ± 0.1 
0.2 ± 0.0
0.1 ± 0.0
0.1 ± 0.0
0.1 ± 0.0
1.2 ± 0.2
<0.01

Fondaparinux
1.7 ± 0.2
1.3 ± 0.1 
>200
10.3 ± 0.8
0.2 ± 0.0
1.5 ± 0.5 
11.7 ± 0.8 
12.3 ± 3.8
21.5 ± 0.5

Ratio fondaparinux/heparin
5.7
3.3
>74
51.5
2
15
117
10.3
>2150



50
n
 = 3). Antibody EW3D10 showed a strong reactivity with fondaparinux, followed by antibodies HS4C3, HS3A8, and EW4G2. The other antibodies showed a relatively weak or no reactivity.



3
e.g.
e.g.
e.g.
Fig. 3
Bar
G
BC
T
 renal tubule






Discussion
N
O
O
et al.
N
O
O
O
O
i.e.
N
-acetylated glucosamine residues. Lack of reactivity with antibody NS4F5 indicates that fondaparinux does not contain a stretch of tri-sulfated disaccharides.
e.g.
2
23
3
4
4
23
O
2
23
], and indicate that biological characteristics are associated with antibody profiles.
6
31
6
19
7
23
]. Antibody NS4F5, which defines a highly sulfated domain, reacted strongly with heparin, but not with the other heparinoids. Reactivity with this antibody may thus be used to obtain information about the risk of a heparinoid to induce HIT.
1
14
21
25
30
33
34
40
3
20
29
18
e.g.
 kidney disease, cancer) characterized by a specific HS profile in tissue, blood, and/or urine.
9
26
26
35
39
35
]. These studies indicate that anti-heparin antibodies may react with heparinoids thereby neutralizing their anticoagulant effect.
Finally, our antibodies may be used for fast industrial screening of heparinoids. A quality check of heparinoid batches may be performed using the antibodies since each heparinoid shows a specific immunoprofile.
In conclusion, this study presents a novel way of characterizing heparinoids using immunoprofiling. Reactivity with antibodies was found indicative for chemical and biological aspects of the heparinoids, and may therefore be used for a fast and simple screening of industrial batches for defined characteristics.


Acknowledgement
This work was supported by grants from The Netherlands Organization for Scientific Research (NWO; program grant 902-27-292), the International Human Frontier Science Program Organization (HFSP; grant RGP0062/2004-C101), and the Dutch Kidney Foundation (grant C05.2152).

References
1.
Achour
A.

Kacem
M.

Dibej
K.

Skhiri
H.

Bouraoui
S.

May
M.


One year course of oral sulodexide in the management of diabetic nephropathy
J. Nephrol.
2005
18
568
574

16299683


2.
Baglin
T.

Barrowcliffe
T.W.

Cohen
A.

Greaves
M.


Guidelines on the use and monitoring of heparin
Br. J. Haematol.
2006
133
19
34
10.1111/j.1365-2141.2005.05953.x

16512825


3.
Bobek
V.

Kovarik
J.


Antitumor and antimetastatic effect of warfarin and heparins
Biomed. Pharmacother.
2004
58
213
219
10.1016/j.biopha.2003.11.007

15183845


4.
Casu
B.

Torri
G.


Structural characterization of low molecular weight heparins
Semin. Thromb. Hemost.
1999
25
Suppl 3
17
25

10549712


5.
Cheng
J.W.


Fondaparinux: a new antithrombotic agent
Clin. Ther.
2002
24
1757
1769
10.1016/S0149-2918(02)80077-7

12501872


6.
Chong
B.H.


Heparin-induced thrombocytopenia
J. Thromb. Hemost.
2003
1
1471
1478
10.1046/j.1538-7836.2003.00270.x

Chong B.H.: Heparin-induced thrombocytopenia. J. Thromb. Hemost. 1, 1471–1478 (2003) 

7.
Chong
B.H.

Magnani
H.N.


Orgaran in heparin-induced thrombocytopenia
Haemostasis
1992
22
85
91

1379968


8.
Dennissen
M.A.

Jenniskens
G.J.

Pieffers
M.

Versteeg
E.M.

Petitou
M.

Veerkamp
J.H.

Kuppevelt
T.H.


Large, tissue-regulated domain diversity of heparan sulfates demonstrated by phage display antibodies
J. Biol. Chem.
2002
277
10982
10986
10.1074/jbc.M104852200

11790764


9.
Dietrich
C.P.

Shinjo
S.K.

Moraes
F.A.

Castro
R.A.

Mendes
A.

Gouvea
T.C.

Nader
H.B.


Structural features and bleeding activity of commercial low molecular weight heparins: neutralization by ATP and protamine
Semin. Thromb. Hemost.
1999
25
Suppl 3
43
50

10549715


10.
Dunn
C.J.

Sorkin
E.M.


Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders
Drugs
1996
52
276
305

8841743


11.
Ernst
S.

Langer
R.

Cooney
C.L.

Sasisekharan
R.


Enzymatic degradation of glycosaminoglycans
Crit. Rev. Biochem. Mol. Biol.
1995
30
387
444
10.3109/10409239509083490

8575190


12.
Fareed
J.

Leong
W.L.

Hoppensteadt
D.A.

Jeske
W.P.

Walenga
J.

Wahi
R.

Bick
R.L.


Generic low-molecular-weight heparins: some practical considerations
Semin. Thromb. Hemost.
2004
30
703
713
10.1055/s-2004-861513

15630677


13.
Farndale
R.W.

Buttle
D.J.

Barrett
A.J.


Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue
Biochim. Biophys. Acta
1986
883
173
177

3091074


14.
Gambaro
G.

Kinalska
I.

Oksa
A.

Pont’uch
P.

Hertlova
M.

Olsovsky
J.

Manitius
J.

Fedele
D.

Czekalski
S.

Perusicova
J.

Skrha
J.

Taton
J.

Grzeszczak
W.

Crepaldi
G.


Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial
J. Am. Soc. Nephrol.
2002
13
1615
1625
10.1097/01.ASN.0000014254.87188.E5

12039991


15.
Jenniskens
G.J.

Oosterhof
A.

Brandwijk
R.

Veerkamp
J.H.

Kuppevelt
T.H.


Heparan sulfate heterogeneity in skeletal muscle basal lamina: demonstration by phage display-derived antibodies
J. Neurosci.
2000
20
4099
4111

10818145


16.
282
(29), 21032–21042 (2007)

17.
Linhardt
R.J.

Gunay
N.S.


Production and chemical processing of low molecular weight heparins
Semin. Thromb. Hemost.
1999
25
Suppl 3
5
16

10549711


18.
Liu
D.

Shriver
Z.

Venkataraman
G.

Shabrawi
Y.

Sasisekharan
R.


Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis
Proc. Natl. Acad. Sci. U.S.A.
2002
99
568
573
10.1073/pnas.012578299

11805315


19.
Maccarana
M.

Lindahl
U.


Mode of interaction between platelet factor 4 and heparin
Glycobiology
1993
3
271
277
10.1093/glycob/3.3.271

8358152


20.
Mousa
S.A.


Anticoagulants in thrombosis and cancer: the missing link
Semin. Thromb. Hemost.
2002
28
45
52
10.1055/s-2002-20559

11885025


21.
Myrup
B.

Hansen
P.M.

Jensen
T.

Kofoed-Enevoldsen
A.

Feldt-Rasmussen
B.

Gram
J.

Kluft
C.

Jespersen
J.

Deckert
T.


Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus
Lancet
1995
345
421
422
10.1016/S0140-6736(95)90403-4

7853952


22.
Neely
J.L.

Carlson
S.S.

Lenhart
S.E.


Tinzaparin sodium: a low-molecular-weight heparin
Am. J. Health-Syst. Pharm.
2002
59
1426
1436

12166042


23.
Petitou
M.

Boeckel
C.A.


A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?
Angew. Chem. Int. Ed. Engl.
2004
43
3118
3133
10.1002/anie.200300640

15199558


24.
Polkinghorne
K.R.

McMahon
L.P.

Becker
G.J.


Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients
Am. J. Kidney Dis.
2002
40
990
995
10.1053/ajkd.2002.36331

12407644


25.
Poplawska
A.

Szelachowska
M.

Topolska
J.

Wysocka-Solowie
B.

Kinalska
I.


Effect of glycosaminoglycans on urinary albumin excretion in insulin-dependent diabetic patients with micro- or macroalbuminuria
Diabetes Res. Clin. Pract.
1997
38
109
114
10.1016/S0168-8227(97)00096-X

9483374


26.
Porsche
R.

Brenner
Z.R.


Allergy to protamine sulfate
Heart Lung
1999
28
418
428
10.1016/S0147-9563(99)70031-2

10580216


27.
Prydz
K.

Dalen
K.T.


Synthesis and sorting of proteoglycans
J. Cell Sci.
2000
113
Pt 2
193
205

10633071


28.
Sagedal
S.

Hartmann
A.

Sundstrom
K.

Bjornsen
S.

Fauchald
P.

Brosstad
F.


A single dose of dalteparin effectively prevents clotting during haemodialysis
Nephrol. Dial. Transplant.
1999
14
1943
1947
10.1093/ndt/14.8.1943

10462275


29.
Sasisekharan
R.

Shriver
Z.

Venkataraman
G.

Narayanasami
U.


Roles of heparan–sulphate glycosaminoglycans in cancer
Nat. Rev. Cancer
2002
2
521
528
10.1038/nrc842

12094238


30.
Skrha
J.

Perusicova
J.

Pont'uch
P.

Oksa
A.


Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients
Diabetes Res. Clin. Pract.
1997
38
25
31
10.1016/S0168-8227(97)00076-4

9347243


31.
Stringer
S.E.

Gallagher
J.T.


Specific binding of the chemokine platelet factor 4 to heparan sulfate
J. Biol. Chem.
1997
272
20508
20514
10.1074/jbc.272.33.20508

9252363


32.
Sugahara
K.

Kitagawa
H.


Recent advances in the study of the biosynthesis and functions of sulfated glycosaminoglycans
Curr. Opin. Struct. Biol.
2000
10
518
527
10.1016/S0959-440X(00)00125-1

11042448


33.
Szelachowska
M.

Poplawska
A.

Topolska
J.

Kinalska
I.

Grimaldi
M.

Szelanowska
M.

Jopdska
J.


A pilot study of the effect of the glycosaminoglycan sulodexide on microalbuminuria in type I diabetic patients
Curr. Med. Res. Opin.
1997
13
539
545

9169256


34.
Tamsma
J.T.

Woude
F.J.

Lemkes
H.H.


Effect of sulphated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathy
Nephrol. Dial. Transplant.
1996
11
182
185

8649631


35.
Ten Dam
G.B.

Kurup
S.

Westerlo
E.M.

Versteeg
E.M.

Lindahl
U.

Spillmann
D.

Kuppevelt
T.H.


O
-sulfated oligosaccharide structures are recognized by anti-heparan sulfate antibody HS4C3
J. Biol. Chem.
2006
281
4654
4662

16373349


36.
Turnbull
J.E.

Hopwood
J.J.

Gallagher
J.T.


A strategy for rapid sequencing of heparan sulfate and heparin saccharides
Proc. Natl. Acad. Sci. U.S.A.
1999
96
2698
2703
10.1073/pnas.96.6.2698

10077574


37.
Turpie
A.G.


Pentasaccharides
Semin. Hematol.
2002
39
158
171
10.1053/shem.2002.34091

12124678


38.
Lest
C.H.

Versteeg
E.M.

Veerkamp
J.H.

Kuppevelt
T.H.


Quantification and characterization of glycosaminoglycans at the nanogram level by a combined azure A–silver staining in agarose gels
Anal. Biochem.
1994
221
356
361
10.1006/abio.1994.1425

7529008


39.
Westerlo
E.M.

Smetsers
T.F.

Dennissen
M.A.

Linhardt
R.J.

Veerkamp
J.H.

Muijen
G.N.

Kuppevelt
T.H.


Human single chain antibodies against heparin: selection, characterization, and effect on coagulation
Blood
2002
99
2427
2433
10.1182/blood.V99.7.2427

11895775


40.
Pijl
J.W.

Woude
F.J.

Geelhoed-Duijvestijn
P.H.

Frolich
M.

Meer
F.J.

Lemkes
H.H.

Es
L.A.


Danaparoid sodium lowers proteinuria in diabetic nephropathy
J. Am. Soc. Nephrol.
1997
8
456
462

9071714


41.
Kuppevelt
T.H.

Dennissen
M.A.

Venrooij
W.J.

Hoet
R.M.

Veerkamp
J.H.


Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney
J. Biol, Chem
1998
273
12960
12966
10.1074/jbc.273.21.12960

9582329


42.
Volpi
N.

Cusmano
M.

Venturelli
T.


Qualitative and quantitative studies of heparin and chondroitin sulfates in normal human plasma
Biochim. Biophys. Acta.
1995
1243
49
58

7827107


43.
Wijnhoven
T.J.

Lensen
J.F.

Rops
A.L.

Vlag
J.

Kolset
S.O.

Bangstad
H.J.

Pfeffer
P.

Hoven
M.J.

Berden
J.H.

Heuvel
L.P.

Kuppevelt
T.H.


Aberrant heparan sulfate profile in the human diabetic kidney offers new clues for therapeutic glycomimetics
Am. J. Kidney Dis.
2006
48
250
261
10.1053/j.ajkd.2006.05.003

16860191





